Table 2.
Kaplan–Meier method analysis of the relationship between PFS and clinical factors in patients in this study
| Parameter | mean PFS (months) | 95%CI | p-value | |
|---|---|---|---|---|
| Lower | Upper | |||
| Age (years) | ||||
| ≥ 65 | 4.13 | 2.848 | 5.413 | 0.462 |
| <65 | 4.95 | 3.479 | 6.411 | |
| Sex | ||||
| Female | 5.66 | 3.656 | 7.66 | 0.178 |
| Male | 4.2 | 3.001 | 5.392 | |
| Treatment line | ||||
| First line | 5.02 | 3.525 | 6.509 | 0.556 |
| Second or higher | 4.3 | 2.878 | 5.716 | |
| Histology | ||||
| Non-small cell | 4.73 | 3.437 | 6.025 | 0.711 |
| Small cell | 4.33 | 2.945 | 5.721 | |
| ICIs type | ||||
| Anti-PD-1 agent | 4.74 | 3.463 | 6.01 | 0.695 |
| Anti-PD-L1 agent | 4.29 | 2.856 | 5.716 | |
| Serum ALB(g/dL) | ||||
| < 37 | 1.85 | 0.675 | 3.017 | <0.001 |
| ≥ 37 | 5.32 | 4.12 | 6.519 | |
| Creatinine (μmol/L) | ||||
| < 61.8 | 3.51 | 2.501 | 4.526 | 0.024 |
| ≥ 61.8 | 5.99 | 4.181 | 7.806 | |
| BMI (kg/m2) | ||||
| < 25 | 3.81 | 2.606 | 5.019 | 0.04 |
| ≥ 25 | 6.25 | 4.446 | 8.054 | |
| LMR | ||||
| < 2.12 | 2.33 | 1.168 | 3.499 | 0.011 |
| ≥ 2.12 | 5.15 | 3.938 | 6.356 | |
| PLR | ||||
| < 135 | 5.05 | 3.187 | 6.903 | 0.612 |
| ≥ 135 | 4.4 | 3.177 | 5.615 | |